New Highly Selective BACE1 Inhibitors and Their Effects on Dendritic Spine Density In Vivo
β-site amyloid precursor protein-cleaving enzyme 1 (BACE1) is considered a therapeutic target to combat Alzheimer’s disease by reducing β-amyloid in the brain. To date, all clinical trials involving the inhibition of BACE1 have been discontinued due to a lack of efficacy or undesirable side effects...
Main Authors: | Katrin Pratsch, Chie Unemura, Mana Ito, Stefan F. Lichtenthaler, Naotaka Horiguchi, Jochen Herms |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-07-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/24/15/12283 |
Similar Items
-
Benzyl Carbamates of 4-Aminosalicylanilides as Possible BACE1 Modulators
by: Petra Majerova, et al.
Published: (2022-11-01) -
pHluorin-BACE1-mCherry Acts as a Reporter for the Intracellular Distribution of Active BACE1 In Vitro and In Vivo
by: Lu Zhao, et al.
Published: (2019-05-01) -
PS1 Affects the Pathology of Alzheimer’s Disease by Regulating BACE1 Distribution in the ER and BACE1 Maturation in the Golgi Apparatus
by: Nuomin Li, et al.
Published: (2022-12-01) -
AAV‐mediated delivery of an anti‐BACE1 VHH alleviates pathology in an Alzheimer's disease model
by: Marika Marino, et al.
Published: (2022-04-01) -
Bioassay-guided isolation of BACE1 inhibitors from Crataegus pinnatifida
by: Yajuan Zhou, et al.
Published: (2023-08-01)